Back to GetFilings.com



UNITED STATES



SECURITIES AND EXCHANGE COMMISSION



WASHINGTON, D.C. 20549





FORM 10-Q




( MARK ONE )




/X/ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act

      of 1934 for the quarterly period ended September 30, 2004.




OR




/ / Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of

    1934 for the transition period from ___________to ________.





Commission File No. 0-16469




INTER PARFUMS, INC.

(Exact name of registrant as specified in its charter)




Delaware                                                                     13-3275609

(State or other jurisdiction of                                     (I.R.S. Employer

incorporation or organization)                                     Identification No.)




551 Fifth Avenue, New York, New York       10176


(Address of Principal Executive Offices)       (Zip Code)




(212) 983-2640

(Registrants telephone number, including area code)




Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days: Yes _X_ No ___




Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the
Exchange Act). Yes ___ No _X_





Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the
latest practicable date.




At November 11, 2004 there were 19,346,417 shares of common stock, par value $.001 per share,
outstanding.




 
































































































































































INDEX


 

   

Page Number

Part I. Financial Information  
     
  Item 1. Financial Statements 1
     
 



Consolidated Balance Sheets

as of September 30, 2004 (unaudited)

and December 31, 2003








2
     
 



Consolidated Statements of Income

for the Three and Nine Months Ended

September 30, 2004 (unaudited)

and September 30, 2003 (unaudited)










3
     
 



Consolidated Statements of Cash Flows

for the Nine Months Ended

September 30, 2004 (unaudited) and

September 30, 2003 (unaudited)










4
     
 

Notes to Consolidated Financial Statements



5
     
  Item 2. Management's Discussion and Analysis of

            Financial Condition and Results of Operations


10
     
  Item 3. Quantitative and Qualitative Disclosures

            About Market Risk


19
     
  Item 4. Controls and Procedures 20
   
Part II. Other Information 21
     
  Item 2. Changes in Securities and Use of Proceeds 21
     
  Item 5. Other Information 21
     
  Item 6. Exhibits and Reports on Form 8-K 22
     
Signatures   23
     
Certifications   24
     




Part I. Financial Information




Item 1. Financial Statements




        In the opinion of management, the accompanying unaudited consolidated financial statements
contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our
financial position, results of operations and cash flows for the interim periods presented. We have
condensed such financial statements in accordance with the rules and regulations of the Securities and
Exchange Commission. Therefore, such financial statements do not include all disclosures required by
accounting principles generally accepted in the United States of America. These financial statements
should be read in conjunction with our audited financial statements for the year ended December 31,
2003 included in our annual report filed on Form 10-K.




        The results of operations for the nine months ended September 30, 2004 are not necessarily
indicative of the results to be expected for the entire fiscal year.












INTER PARFUMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands except share and per share data)




 



ASSETS
 
























































































































September 30,

2004

 

December 31,

2003

  (unaudited)  
Current assets:  
   Cash and cash equivalents   $ 34,747
  $ 58,958
   Account receivable, net   78,171   63,467
   Inventories   68,500   54,255
   Receivables, other   1,925   1,631
   Other current assets   2,413   1,638
   Income tax receivable   303   1,110
   Deferred tax asset  

2,394

 

1,381

 
      Total current assets   188,453   182,440
 
Equipment and leasehold improvements, net   5,896   4,967
   
Trademarks and licenses, net   31,597   6,323
   
Goodwill   4,670   --
   
Other assets

518



271

   
   

$ 231,134

 

$ 194,001






LIABILITIES AND SHAREHOLDERS' EQUITY




























































































































































See notes to consolidated financial statements.




Current liabilities:  
   Loans payable - banks   $ 7,845
  $ 121
   Current portion of long-term debt   3,945   --
   Accounts payable   29,486   45,152
   Accrued expenses   29,401   17,403
   Income taxes payable   2,483   3,411
   Dividends payable  

575

 

383

 
      Total current liabilities  

73,735

 

66,470

 
Long-term debt, less current portion  

14,797

 

--

   
Deferred tax liability  

2,403

 

1,417

   
Put options  

857

 

--

   
Minority interest  

25,277

 

21,198

   
Shareholders' equity:  
   Preferred stock, $.001 par; authorized

     
1,000,000 shares; none issued
 
   Common stock, $.001 par; authorized 100,000,000 shares;

     
outstanding 19,175,249 and 19,164,186 shares at

     
September 30, 2004 and December 31, 2003, respectively
 





19









19
   Additional paid-in capital   34,412 34,363
   Retained earnings   97,868 87,376
   Accumulated other comprehensive income   8,012 9,404
   Treasury stock, at cost, 7,180,579 common

     
shares at September 30, 2004 and December 31, 2003
 



(26,246)





(26,246)

   
 

114,065



104,916

   
   

$ 231,134

 

$ 194,001

       
 










CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)


 

    Three Months Ended

September 30,
  Nine Months Ended

September 30,


























































































































































































































































































































































See notes to consolidated financial statements.






2004

 

2003

 

2004

 

2003

 
Net sales   $ 67,090   $ 57,401   $ 172,215   $ 136,358
 
Cost of sales  

33,822

 

29,890

 

86,541

 

70,832

 
Gross margin   33,268   27,511   85,674   65,526
 
Selling, general and administrative  

25,261

 

19,090

 

60,643

 

46,663

 
Income from operations  

8,007

 

8,421

 

25,031

 

18,863

 
Other expenses (income):  
   Interest expense   239   56   448   223
   (Gain) loss on foreign currency   19   (489)   503   (344)
   Interest and dividend income   (139)   (183)   (583)   (640)
   Loss on subsidiary's issuance of stock  

--

 

--

 

25

 

155

   
 

119

 

(616)

 

393

 

(606)

   
Income before income taxes   7,888   9,037   24,638   19,469
     
Income taxes  

2,658

 

3,177

 

8,611

 

6,819

   
Net income before minority interest   5,230   5,860   16,027   12,650
   
Minority interest in net income

  
of consolidated subsidiary
 



1,193

 



1,176

 



3,810

 



2,526

   
Net income  

$ 4,037

 

$ 4,684

 

$ 12,217

 

$ 10,124

   
Net income per share:  
Basic   $0.21   $0.25   $0.64   $0.53
Diluted  

$0.20

 

$0.23

 

$0.60

 

$0.51

   
Weighted average number of shares
outstanding:
 
Basic   19,171   19,024   19,170   19,000
Diluted  

20,397

 

20,182

 

20,530

 

19,997









CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)


 

Nine months ended

September 30,































































































































































































































































See notes to consolidated financial statements.



Notes to Consolidated Financial Statements




1. Significant Accounting Policies:




The accounting policies we follow are set forth in the notes to our financial statements included in
our Form 10-K which was filed with the Securities and Exchange Commission for the year ended
December 31, 2003. We also discuss such policies in Part I, Item 2, Management's Discussion
and Analysis of Financial Condition and Results of Operations, included in this Form 10-Q.




2. Stock- based Compensation:



The Company accounts for stock-based employee compensation under Accounting Principles
Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations
("APB 25"). The Company has adopted the disclosure-only provisions of SFAS No. 123,
"Accounting for Stock-Based Compensation" and SFAS No. 148, "Accounting for Stock-Based
Compensation - Transition and Disclosure", which was released in December 2002 as an
amendment of SFAS No. 123.




The Company applies APB No. 25 and related interpretations in accounting for its stock option
incentive plans. The following table illustrates the effect on net income and earnings per share as
if the fair value based method had been applied to all awards.





2004

 

2003

Cash flows from operating activities:  
   Net income   $ 12,217
  $ 10,124
   Adjustments to reconcile net income to

     
net cash provided by (used in) operating activities:
 
 
         Depreciation and amortization   2,484   2,088
         Minority interest in net income of consolidated


            subsidiary
 


3,810
 


2,526
         Deferred tax (benefit) provision   (1)   390
         Loss on subsidiary's issuance of stock   25   156
         Change in fair value of put options   (74)   --
   Changes in:    
         Accounts receivable, net   (15,126)   (21,572)
         Inventories   (14,025)   (5,144)
         Other assets   (1,044)   (93)
         Accounts payable and accrued expenses   (8,510)   8,814
         Income taxes payable, net  

(47)

 

2,052

 
            Net cash used in operating activities  

(20,291)

 

(659)

   
Cash flows from investing activities:  
   Purchase of equipment and leasehold improvements   (2,171)   (1,599)
   Payment for licenses acquired   (20,258)   --
   Acquisition of businesses, net of cash acquired  

(4,416)

 

--

 
            Net cash used in investing activities  

(26,845)

 

(1,599)

 
Cash flows from financing activities:  
   Increase in loans payable - bank   7,316   4,180
   Proceeds from long-term debt   19,636   --
   Repayment of long-term debt   (982)   --
   Proceeds from sale of stock of subsidiary   168   356
   Proceeds from exercise of options   49   94
   Dividends paid   (1,534)   (1,047)
   Dividends paid to minority interest   (776)   (409)
   Purchase of treasury stock  

--

 

(64)

 
             Net cash provided by financing activities  

23,877

 

3,110

 
Effect of exchange rate changes on cash  

(952)

 

2,781

 
Net (decrease) increase in cash and cash equivalents   (24,211)   3,633
 
Cash and cash equivalents - beginning of period  

58,958

 

38,290

 
Cash and cash equivalents - end of period  

$ 34,747

 

$ 41,923

 
Supplemental disclosure of cash flow information  
   Cash paid for:  
      Interest   $ 412   $ 561
      Income taxes   $ 9,203   $ 4,905





(In thousands, except per share data)

Three months ended

September 30,

Nine months ended

September 30,



























































































The weighted average fair values of the options granted during the 2004 and 2003 periods are
estimated as $6.89 and $2.07 per share, respectively, on the date of grant using the Black-Scholes
option pricing model with the following assumptions: dividend yield 0.5% in 2004 and 1.0% in
2003; volatility of 50% in both 2004 and 2003; risk-free interest rates at the date of grant, 1.81%
in 2004 and 1.70% in 2003; and an expected life of the option of two years.








Notes to Consolidated Financial Statements




3. Comprehensive Income:




2004 2003 2004 2003
Reported net income $ 4,037 $ 4,684 $ 12,217 $ 10,124
Stock-based employee compensation expense included
in

   reported net income, net of related tax effect


--


--


--


--
Stock-based employee compensation determined under

  
the fair value based method, net of tax effect




- --





- --





(93)





(22)

       
Pro forma net income

$ 4,037



$ 4,684



$ 12,124



$ 10,102

       
Income per share, as reported:        
   Basic $ 0.21 $ 0.25 $ 0.64 $ 0.53
   Diluted

$ 0.20



$ 0.23



$ 0.60



$ 0.51

Pro forma net income per share:
   Basic $ 0.21 $ 0.25 $ 0.63 $ 0.53
   Diluted

$ 0.20



$ 0.23



$ 0.59



$ 0.51






(In thousands)

Three months ended

September 30,

Nine months ended

September 30,


















































4. Geographic Areas:




European operations are primarily conducted in France and primarily represent sales of prestige
brand name fragrances. Information related to domestic and foreign operations is as follows:




2004 2003 2004 2003
Comprehensive income:
   Net income $ 4,037 $ 4,684 $ 12,217 $ 10,124
   Other comprehensive income, net of tax:
      Foreign currency translation adjustment 1,515 1,055 (1,345) 5,505
      Change in fair value of derivatives used for
hedging


(9)



24



(47)



117

     
Comprehensive income

$ 5,543



$ 5,763



$ 10,825



$ 15,746






(In thousands)

Three months ended

September 30,

Nine months ended

September 30,















































































5. Reclassifications:





Certain items in the accompanying Consolidated Statements of Income have been reclassified to
conform to current period presentation.




6. Earnings Per Share:





Basic earnings per share are computed using the weighted average number of shares outstanding
during each period. Diluted earnings per share are computed using the weighted average number
of shares outstanding during each period, plus the incremental shares outstanding assuming the
exercise of dilutive stock options.





Notes to Consolidated Financial Statements




6. Earnings Per Share (continued):




The following table sets forth the computation of basic and diluted earnings per share:





2004 2003 2004 2003
Net Sales:
   United States $ 10,071 $ 11,699 $ 30,256 $ 32,212
   Europe 57,835 45,887 142,960 104,429
   Eliminations

(816)



(185)



(1,001)



(283)

 
 

$ 67,090



$ 57,401



$ 172,215



$ 136,358

 
Net Income:  
   United States $ 382 $ 844 $ 725 $ 1,836
   Europe 3,773 3,851 11,620 8,296
   Eliminations

(118)



(11)



(128)



(8)

 


$ 4,037



$ 4,684



$ 12,217



$ 10,124






(In thousands) Three months ended

September 30,
Nine months ended

September 30,
























































Not included in the above computation is the effect of anti-dilutive potential common
shares which consist of options to purchase 220,000 and 83,000 shares of common stock
for the three and nine month periods ended September 30, 2004, respectively, and 0 and
271,000 for the three and nine months ended September 30, 2003, respectively.





7. Inventories:




Inventories consist of the following:




2004 2003 2004 2003
Numerator:
   Net income

$ 4,037



$ 4,684



$ 12,217



$ 10,124

 
Denominator:  
   Weighted average shares 19,171 19,024 19,170 19,000
   Effect of dilutive securities:
      Stock options

1,226



1,158



1,360



997

 
Denominator for diluted earnings per share

20,397



20,182



20,530



19,997
























8. Acquisition of Business:




In April 2004, the Company's French subsidiary, Inter Parfums, S.A., ("IPSA") acquired a 67.5%
interest in Nickel S.A. ("Nickel") for approximately $8.3 million in cash including a capital
infusion of $2.8 million made in June 2004, aggregating approximately $4.4 million, net of cash
acquired. In accordance with the purchase agreement, each of the minority shareholders has an
option to put their remaining interest in Nickel to IPSA from January 2007 through June 2007.
Based on an independent valuation, management has valued the put options at $0.93 million as of
the date of acquisition, revised from $1.92 million used in June based on a preliminary valuation,
and has recorded a long-term liability and increased goodwill accordingly. These options are
carried at fair value as determined by management as of September 30, 2004, which resulted in a
gain of $74,000, which is included in selling, general and administrative expense in the
accompanying consolidated statements of income.



Notes to Consolidated Financial Statements




8. Acquisition of Business (continued):



The purchase price for the minority shares will be based upon a formula applied to Nickel's sales
for the year ending December 31, 2006, pro rated for the minority holders' equity in Nickel or at a
price approximately 7% above the recent purchase price. In addition, the Company has the right
to call the stock based on the same formula and price. The acquisition has been accounted for as
a business combination and the results of Nickel have been included in the Company's
consolidated financial statements from the date of the acquisition.



Net sales of Nickel products for the period April 1, 2004 through September 30, 2004 aggregated
$2.2 million and net income for the same period was insignificant. For the year ended March 31,
2004, prior to the acquisition, Nickel generated net sales of approximately $6 million.



The Company has not yet completed the evaluation and allocation of the purchase price for the
2004 acquisition, as the appraisals associated with the valuations of certain intangible assets are
preliminary. The Company does not believe that the final appraisals will materially modify the
current preliminary purchase price allocation.



9. Acquisition of Licenses:




[1] In June 2004, IPSA entered into an exclusive, worldwide license agreement with Lanvin
S.A. ("Lanvin") to create, develop and distribute fragrance lines under the Lanvin brand name.
The fifteen-year license agreement took effect July 1, 2004 and provided for an upfront non-recoupable license fee of $19.2 million, the purchase of existing inventory of $7.6 million, and
requires advertising expenditures and royalty payments in line with industry practice, as well as,
the assumption of certain pre existing contractual obligations.




[2] In October 2004, IPSA entered into a new long-term fragrance license with Burberry.
The agreement has a 12.5-year term with an option to extend the license by an additional 5-years
subject to mutual agreement. This new agreement replaces the existing license and provides for
an increase in the royalty rate effective as of July 1, 2004 and additional resources to be devoted
to marketing commencing in 2005. In connection with the new license agreement IPSA agreed
to pay to Burberry an upfront non-recoupable license fee of approximately $3.6 million, which
amount is included in the accompanying balance sheet as of September 30, 2004.




10. Long-Term Debt:




In connection with the acquisition of the Lanvin license referred to above, IPSA initially financed
the license fee by utilizing $18.0 million from one of its short-term credit facilities. In July, IPSA
converted the loan into a $19.2 million five-year credit agreement. The long-term credit facility,
which bears interest at 0.60% above the Eurobor rate, provides for principal to be repaid in 20
equal quarterly installments of $0.96 million and requires the maintenance of a debt equity ratio of
less than one.











Notes to Consolidated Financial Statements




11. Shareholders' Equity:




In October 2004, both the Chief Executive Officer and the President exercised an aggregate of
65,400 and 97,600 outstanding stock options, respectively, of the Company's common stock. The
exercise prices of $167,000 for the Chief Executive Officer and $249,000 for the President were
paid by each of them tendering to the Company 13,055 and 19,482 shares, respectively, of the
Company's common stock, previously owned by them, valued at $12.805 per share, the fair
market value on the date of exercise. All shares issued pursuant to these option exercises were
issued from our treasury stock. In addition, the Chief Executive Officer tendered an additional
14,395 shares for payment of withholding taxes resulting from his option exercise. As a result of
this transaction, the Company expects to receive a tax benefit of approximately $600,000, which
will be reflected as an increase to additional paid-in capital in the Company's consolidated
financial statements for the year ended December 31, 2004.




Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF



FINANCIAL CONDITION AND RESULTS OF OPERATIONS




    Forward Looking Information



    Statements in this document, which are not historical in nature, are forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may
cause the actual results to be materially different from projected results. Given these risks, uncertainties
and other factors, you are cautioned not to place undue reliance on the forward-looking statements.




    Such factors include renewal of existing license agreements, effectiveness of sales and
marketing efforts and product acceptance by consumers, dependence upon management, competition,
currency fluctuation and international tariff and trade barriers, governmental regulation and possible
liability for improper comparative advertising or "Trade Dress".



    Overview




    We operate in the fragrance and cosmetic industry, and manufacture, market and distribute a wide
array of fragrances, cosmetics and health and beauty aids. We manage our business in two segments,
French based operations and United States based operations. We specialize in prestige perfumes and
mass-market perfumes, cosmetics and health and beauty aids. Most of our prestige products are
produced and marketed by our 75% owned subsidiary in Paris, Inter Parfums, S.A., which is also a
publicly traded company as 25% of Inter Parfums, S.A. shares trade on the Paris Bourse. Prestige
cosmetics and prestige skin care products represent less than 5% of consolidated net sales. Our mass-market products are primarily produced and marketed by our United States operations.







    Our prestige product lines, which are manufactured and distributed by us primarily under
license agreements with brand owners, represented approximately 83% of net sales for the nine-month
period ended September 30, 2004. Since 1992 we have built a portfolio of brands under licenses
which include Burberry, S.T. Dupont, Paul Smith, Christian Lacroix, Celine, Diane von Furstenberg
and Lanvin, which are distributed in over 120 countries around the world. In terms of sales, Burberry is
our most significant license, and sales of Burberry products represented
approximately 62% and 54% of net sales for
the nine-month periods ended September 30, 2004 and 2003, respectively.



    On October 12, 2004, we entered into a new long-term fragrance license with Burberry. The
agreement has a 12.5-year term with an option to extend the license by an additional 5-years subject to
mutual agreement. This new agreement replaces the existing license and provides for an increase in the
royalty rate effective as of July 1, 2004 and additional resources to be devoted to marketing
commencing in 2005. In anticipation of these new terms and to mitigate the associated expenses, we are
fine-tuning our operating model. This new model is expected to include increased selling prices, modified cost
sharing arrangements with suppliers and distributors, and involves the future formation of joint ventures or Company-owned subsidiaries within key markets. While we anticipate a continued short-term impact on our
bottom line, particularly for the rest of 2004 and early 2005, the growth potential offered by this
international luxury brand makes us confident about our future long-term prospects.



    In April 2004, we acquired a 67.5% interest in Nickel S.A. ("Nickel") for approximately
$8.3 million in cash, including a capital infusion of $2.8 million made in June 2004, aggregating
approximately $4.4 million, net of cash acquired. Nickel produces a full line of high-end skin care
products for men which are sold in prestige department and specialty stores throughout Western
Europe and the United States, as well as through its men's spas in Paris, New York and its licensed
spa in San Francisco.





    In June 2004, IPSA entered into an exclusive, worldwide license agreement with Lanvin to
create, develop and distribute fragrance lines under the Lanvin brand name. The fifteen-year license
agreement takes effect July 1, 2004 and provided for an upfront license fee of $19.2 million and the
purchase of existing inventory of $7.6 million.




    We have two licenses with affiliates of our strategic partner, LV Capital, USA Inc. ("LV
Capital"), a wholly-owned subsidiary of LVMH Moët Hennessy Louis Vuitton S.A. LV Capital owns
approximately 18% of our outstanding common shares. In May 2000 we entered into an exclusive
worldwide license for prestige fragrances for the Celine brand, and in March 1999 we entered into an
exclusive worldwide license for Christian Lacroix fragrances. Both licenses are subject to certain
minimum sales requirements, advertising expenditures and royalty payments as are customary in our
industry. We believe that our association with LV Capital has enhanced our credibility in the cosmetic
industry, which should lead us to additional opportunities in our industry that might not have been
otherwise available to us.




    Our United States operations, which primarily consists of mass market product lines,
represented 17% of sales for the nine-month period ended September 30, 2004, and are comprised of
alternative designer fragrances, cosmetics, health and beauty aids and personal care products. These
lines are sold under trademarks owned by us or pursuant to license agreements we have for the
trademarks Jordache and Tatiana.




    We grow our business in two distinct ways. First, we grow by adding new brands to our
portfolio, either through new licenses or out-right acquisition. Second, we grow through the creation of
product line extensions within the existing brands in our portfolio. Every two to three years, we create a
new family of fragrances for each brand in our portfolio.




    Our business is not very capital intensive, and it is important to note that we do not own any
manufacturing facilities. Rather, we act as a general contractor and source our needed components
from our suppliers. These components are received at one of our distribution centers and then, based
upon production needs, the components are sent to one of several outside fillers which manufacture the
finished good for us and ship it back to our distribution center.





    Discussion of Critical Accounting Policies




    We make estimates and assumptions in the preparation of our financial statements in conformity
with accounting principles generally accepted in the United States of America. Actual results could
differ significantly from those estimates under different assumptions and conditions. We believe the
following discussion addresses our most critical accounting policies, which are those that are most
important to the portrayal of our financial condition and results of operations. These accounting policies
generally require our management's most difficult and subjective judgments, often as a result of the need
to make estimates about the effect of matters that are inherently uncertain. The following is a brief
discussion of the more critical accounting policies that we employ.




    Revenue Recognition




    We sell our products to department stores, perfumeries, mass market retailers, supermarkets and
domestic and international wholesalers and distributors. Sales of such products by our domestic
subsidiaries are denominated in U.S. dollars and sales of such products by our foreign subsidiaries are
primarily denominated in either Euros or U.S. dollars. Accounts receivable reflect the granting of credit
to these customers. We generally grant credit based upon our analysis of the customer's financial
position as well as previously established buying patterns. Generally, we do not bill customers for
shipping and handling costs and, accordingly, we classify such costs as selling and administrative
expenses. We recognize revenues when merchandise is shipped and the risk of loss passes to the
customer. Net sales are comprised of gross revenues less returns, and trade discounts and allowances.




    Sales Returns




    Generally, we do not permit customers to return their unsold products. However, on a case-by-case
basis we occasionally allow customer returns. We regularly review and revise, as deemed necessary,
our estimate of reserves for future sales returns based primarily upon historic trends and relevant current
data. We record estimated reserves for sales returns as a reduction of sales, cost of sales and accounts
receivable. Returned products are recorded as inventories and are valued based upon estimated
realizable value. The physical condition and marketability of returned products are the major factors we
consider in estimating realizable value. Actual returns, as well as estimated realizable values of returned
products, may differ significantly, either favorably or unfavorably, from our estimates, if factors such as
economic conditions, inventory levels or competitive conditions differ from our expectations.




    Promotional Allowances




    We have various performance-based arrangements with certain retailers to reimburse them for
all or a portion of their promotional activities related to our products. These arrangements primarily
allow customers to take deductions against amounts owed to us for product purchases. Estimated
accruals for promotions and co-operative advertising programs are recorded in the period in which the
related revenue is recognized. We review and revise the estimated accruals for the projected costs for
these promotions. Actual costs incurred may differ significantly, either favorably or unfavorably, from
estimates if factors such as the level and success of the retailers' programs or other conditions differ
from our expectations.




    Inventories




    Inventories are stated at the lower of cost or market value. Cost is principally determined by
the first-in, first-out method. We record adjustments to the cost of inventories based upon our sales
forecast and the physical condition of the inventories. These adjustments are estimates, which could
vary significantly, either favorably or unfavorably, from actual requirements if future economic
conditions or competitive conditions differ from our expectations.




    Equipment and Other Long-Lived Assets




    Equipment, which includes tools and molds, is recorded at cost and is depreciated on a
straight-line basis over the estimated useful lives of such assets. Changes in circumstances such as
technological advances, changes to our business model or changes in our capital spending strategy can
result in the actual useful lives differing from our estimates. In those cases where we determine that the
useful life of equipment should be shortened, we would depreciate the net book value in excess of the
salvage value, over its revised remaining useful life, thereby increasing depreciation expense. Factors
such as changes in the planned use of equipment, or market acceptance of products, could result in
shortened useful lives.




    Long-lived assets, including trademarks, licenses and goodwill, are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of any such asset may
not be recoverable. If the sum of the undiscounted cash flows (excluding interest) is less than the
carrying value, then we recognize an impairment loss, measured as the amount by which the carrying
value exceeds the fair value of the asset. The estimate of undiscounted cash flow is based upon, among
other things, certain assumptions about expected future operating performance. Our estimates of
undiscounted cash flow may differ from actual cash flow due to, among other things, economic
conditions, changes to our business model or changes in consumer acceptance of our products. In
those cases where we determine that the useful life of other long-lived assets should be shortened, we
would depreciate the net book value in excess of the salvage value (after testing for impairment as
described above), over the revised remaining useful life of such asset thereby increasing amortization
expense.




    Results of Operations




    Three and Nine Months Ended September 30, 2004 as Compared to the Three

   
and Nine Months Ended September 30, 2003






(In thousands) September 30,

 2004
December 31,

 2003
Raw materials and component parts $ 23,042 $ 19,776
Finished goods

45,458



34,479



$ 68,500



$ 54,255










 
Net sales Three months ended

September 30,
Nine months ended

September 30,






























































    Net sales for the three months ended September 30, 2004 increased 17% to $67.1 million, as
compared to $57.4 million for the corresponding period of the prior year. At comparable foreign
currency exchange rates, net sales increased 11% for the period.





    Net sales for the nine months ended September 30, 2004 increased 26% to $172.2 million, as
compared to $136.4 million for the corresponding period of the prior year. At comparable foreign
currency exchange rates, net sales increased 21% for the period.





    Prestige product sales increased 26% for the three months ended September 30, 2004 and 38%
for the nine months ended September 30, 2004, as compared to the corresponding periods of the prior
year. The excellent performance of Burberry London, Burberry Weekend, Burberry Touch, as well as
the Burberry Brit women's collection all contributed to the growth in prestige product sales. In addition,
during the third quarter of 2004, the Burberry Brit men's line was launched in the UK, select countries in
Western Europe and in the US and will continue to be rolled out over the coming months in South
America and the Middle East.





    The year 2004 also included several brand extensions. During the second quarter of 2004, we
launched a limited edition warm weather seasonal fragrance for our Celine and Christian Lacroix brands.
In July, we unveiled new fragrance families for both S.T. Dupont and Paul Smith and began distribution
for Lanvin products, our newest brand under license. In early 2005, we plan to introduce new Christian
Lacroix and Celine fragrance families. In addition, our first new Lanvin fragrance is under development in
preparation for a late 2005 or early 2006 launch.





    With respect to our mass-market product lines, net sales were off 22% for the three months
ended September 30, 2004 and 12% for the nine months ended September 30, 2004, as compared to
the corresponding periods of the prior year. The decline in mass-market product sales is primarily the
result of a decline in export sales to customers in Mexico and Central and South America. The
economic environment in that area has been weak throughout 2004 and we have continued to closely
monitor our credit risk in those territories and are willing to forego sales volume to minimize our overall
credit exposure.





    Our new product development program for all of our product groups is well under way, and as
previously mentioned, we have rolled out new products throughout 2004 and have several new product
launches planned for 2005. In addition, we are actively pursuing other new business opportunities.
However, we cannot assure you that any new license or acquisitions will be consummated.





    In April 2004, the Company's French subsidiary, Inter Parfums, S.A., ("IPSA") acquired a
67.5% interest in Nickel S.A. ("Nickel") for approximately $8.3 million in cash including an additional
capital infusion of $2.8 million made in June 2004, aggregating approximately $4.4 million, net of cash
acquired.





    Established in 1996 by Philippe Dumont, Nickel has developed two innovative concepts in the
world of cosmetics: spas exclusively for male customers and skin care product lines for men. The
Nickel range of some fifteen skin care products for the face and body is sold through prestige
department and specialty stores primarily in France (500 outlets), the balance of Western Europe (900
outlets) and in the United States (300 outlets), as well as through its men's spas in Paris, New York
and, most recently, its licensed spa in San Francisco.





    Net sales of Nickel products for the period April 1, 2004 through September 30, 2004
aggregated $2.2 million and net income for the same period was insignificant. For the year ended
March 31, 2004, prior to the acquisition, Nickel generated net sales of approximately $6 million.





    In June 2004, IPSA entered into an exclusive, worldwide license agreement with Lanvin S.A.
("Lanvin") to create, develop and distribute fragrance lines under the Lanvin brand name. The fifteen-year license agreement took effect July 1, 2004.





    A synonym of luxury and elegance, the Lanvin fashion house, founded in 1889 by Jeanne
Lanvin, expanded into fragrances in the 1920s. Today, Lanvin fragrances occupy important positions in
the selective distribution market in France, Europe and Asia particularly with the lines Arpège (created
in 1927), Lanvin L'Homme (1997), Oxygène (2000), Eclat d'Arpège (2002) and Vetyver (2003).



    In October 2004, we entered into a new long-term fragrance license with Burberry. This new
agreement replaces the existing license and provides for an increase in the royalty rate effective as of
July 1, 2004 and additional resources to be devoted to marketing commencing in 2005. In anticipation
of these new terms and to mitigate the associated expenses, we are fine-tuning our operating model. This
new model is expected to include increased selling prices, modified cost sharing
arrangements with suppliers and distributors,
and involves the future formation of joint ventures or Company-owned subsidiaries within key markets.
While we anticipate a continued short-term impact on our bottom line, particularly for the rest of 2004
and early 2005, the growth potential offered by this international luxury brand makes us confident about our
future long-term prospects.





(In millions)




2004



%

Change




2003

 




2004

%

Change





2003

 
                 
Prestige product sales $ 58.4 26% $ 46.3   $ 143.3 38% $ 103.7  
Mass market product sales

8.7

( 22% )

11.1

 

28.9

( 12% )

32.7

 
                 
Total net sales

$ 67.1

17%

$ 57.4

 

$ 172.2

26%

$ 136.4

 







Gross margins Three months ended

September 30,
Nine months ended

September 30,



















































































    Gross profit margin was 50% for both the three and nine-month periods ended September 30,
2004, as compared to 48% for both of the corresponding periods of the prior year. Sales of products
from our primarily French based prestige fragrance lines generate a higher gross profit margin than sales
of our primarily United States based mass-market product lines. A decline of between 2% and 3% in
gross margin as a percentage of sales for United States operations was mitigated by the gross margin
improvement resulting the net sales growth rate achieved in prestige product lines for both the three and
nine-month periods ended September 30, 2004, as compared to the corresponding periods of the prior
year.







(In millions)

2004

 

2003

 

2004

 

2003

 
                 
Net sales $ 67.1   $ 57.4   $ 172.2   $ 136.4  
Cost of sales

  33.8

 

   29.9

 

     86.5

 

      70.8

 
                 
Gross margin

$ 33.3

 

$ 27.5

 

$ 85.7

 

$ 65.6

 
                 
Gross margin as a percent of net sales


50%

 


48%

 


50%

 


48%

 







Selling, general &
administrative
Three months ended

September 30,
Nine months ended

September 30,






















































    Selling, general and administrative expense increased 32% and 30% for the three and nine-month
periods ended September 30, 2004, respectively, as compared to the corresponding periods of the prior
year. As a percentage of sales selling, general and administrative was 38% and 35% of sales for the three
and nine-month periods ended September 30, 2004, respectively, as compared to 33% and 34% for the
corresponding periods of the prior year. The increase in selling, general and administrative expenses as a
percentage of sales for the three-month period ended September 30, 2004, as compared to the
corresponding period of the prior year is primarily the result of increased royalties required under our
new license with Burberry.





    In addition, growth in our prestige product lines require higher selling, general and administrative
expenses because promotion and advertising are prerequisites for sales of designer prestige products.
We develop a complete marketing and promotional plan to support our growing portfolio of prestige
brands and to build upon each brand's awareness. Promotion and advertising included in selling, general
and administrative expenses was approximately 10% and 11% of prestige product sales for the three and
nine-month periods ended September 30, 2004, as compared to 11% and 12% for the three and nine-month periods ended September 30, 2003. Our mass-market product lines do not require extensive
advertising and therefore, more of our selling, general and administrative expenses are fixed rather than
variable.





    As previously reported, IPSA was a party to litigation with Jean Charles Brosseau, S.A.
("Brosseau"), the owner of the Ombre Rose trademark. In October 1999, IPSA received notice of a
judgment in favor of Brosseau, which awarded damages of approximately $0.85 million (at current
exchange rates). On appeal, in February 2001, the Court required IPSA to pay $0.14 million as an
advance for damages claimed by Brosseau.




    In February 2004, the Court of Appeal ordered IPSA to pay total damages of $0.39 million of which
$0.14 million has already been advanced. Brosseau had until the end of May 2004 to appeal this
decision. No appeal has been filed, and therefore, in May 2004, IPSA reversed its remaining litigation
reserve aggregating approximately $0.46 million. This reversal is included as a reduction of
administrative expenses in the accompanying consolidated statement of income.




    Interest expense aggregated $0.2 million and $0.4 million for the three and nine-month periods ended
September 30, 2004, as compared to $0.1 million and $0.2 million for the corresponding periods of the
prior year. We use the credit lines available to us, as needed, to finance our working capital needs and
short-term financing for acquisitions. In connection with the acquisition of the Lanvin license referred to
above, IPSA financed the license fee by utilizing one of its short-term credit facilities which in July 2004
was converted into a $19.2 million five-year credit agreement.



    Foreign currency gains and (losses) aggregated $0.5 million and ($0.3) million for the nine-month periods ended September 30, 2004 and September 30, 2003, respectively. Occasionally, we
enter into foreign currency forward exchange contracts to manage exposure related to certain foreign
currency commitments.




    Our effective income tax rate was 34% for the three months ended September 30, 2004, as
compared to 35% for the corresponding period of the prior year. Our effective income tax rate was
35% for both the nine months ended September 30, 2004 and September 30, 2003. These rates differ
from statutory rates due to the effect of state and local taxes and tax rates in foreign jurisdictions. No
significant changes in tax rates were experienced nor were any expected in jurisdictions where we
operate.




    Net income was $4.0 million for the three months ended September 30, 2004, as compared to $4.7
million for the corresponding period of the prior year. Net income was $12.2 million for the nine months
ended September 30, 2004, as compared to $10.1 million for the corresponding period of the prior
year.




    Diluted earnings per share was $0.20 for the three months ended September 30, 2004, as
compared to $0.23 for the corresponding period of the prior year. Diluted earnings per share was
$0.60 for the nine months ended September 30, 2004, as compared to $0.51 for the corresponding
period of the prior year.




    Weighted average shares outstanding aggregated 19.2 million for both the three and nine-month
periods ended September 30, 2004, as compared to 19.0 million for the corresponding periods of the
prior year. On a diluted basis, average shares outstanding were 20.4 million and 20.5 million,
respectively, for the three and nine-month periods ended September 30, 2004, as compared to 20.2
million and 20.0 million, respectively, for the corresponding periods of the prior year. The increase in
the average diluted shares outstanding is the result of the effect of dilutive securities resulting from an
increase in our average stock price. The average stock price of our common shares was $20.87 per
share for the nine-month period ended September 30, 2004, as compared to $8.16 per share for the
corresponding period of the prior year.




    Liquidity and Capital Resources




    Our financial position remains strong. At September 30, 2004, working capital aggregated
$115 million and we had a working capital ratio of 2.6 to 1. Cash and cash equivalents aggregated
$34.7 million.




    In April 2004, IPSA acquired a 67.5% interest in Nickel for approximately $8.3 million in cash
including an additional capital infusion of $2.8 million made in June 2004, aggregating approximately
$4.4 million, net of cash acquired. We funded this acquisition with cash on hand and do not expect it to
have any further significant effect on our financial position.




    In June 2004, IPSA entered into an exclusive, worldwide license agreement with Lanvin to create,
develop and distribute fragrance lines under the Lanvin brand name. The fifteen-year license agreement
takes effect July 1, 2004 and provided for an upfront license fee of $19.2 million and the purchase of
existing inventory of $7.6 million. IPSA initially financed the license fee by utilizing $18.0 million from
one of its short-term credit facilities. In July, IPSA converted the loan into a $19.2 million five-year
credit agreement. This long-term credit facility, which bears interest at 0.60% above the Eurobor rate,
provides for principal to be repaid in 20 equal quarterly installments of $0.96 million and requires the
maintenance of certain financial covenants.




    In October 2004, IPSA entered into a new long-term fragrance license with Burberry. This new
agreement replaces the existing license and provides for an increase in the royalty rate effective as of
July 1, 2004 and additional resources to be devoted to marketing commencing in 2005. In connection
with the new license agreement IPSA agreed to pay to Burberry an upfront license fee of approximately
$3.6 million.




    Our short-term cash requirements are expected to be met by available cash at September 30, 2004,
cash generated by operations and short-term credit lines provided by domestic and foreign banks. The
principal credit facilities consist of a $12.0 million unsecured revolving line of credit provided by a
domestic commercial bank and approximately $45.0 million in credit lines provided by a consortium of
international financial institutions. Historically, borrowings under these facilities have been minimal as
we typically use our cash to finance all of our working capital needs. However, as of September 30,
2004 we drew down approximately $7.8 million on our credit lines to help finance our working capital
needs.




    Cash used in operating activities aggregated $20.3 million for the nine-month period ended
September 30, 2004, as compared to cash used in operating activities of $0.7 million for the
corresponding period of the prior year. We finance our growth primarily with working capital and to a
lesser extent our available credit lines. Cash used in operating activities for 2004 reflects a significant
increase in inventory and accounts receivable (approximately $14.0 million and $15.1 million,
respectively). The increase in accounts receivable, which represents a 23% increase from the
December 31, 2003 accounts receivable balance, is not unusual considering the Company's sales
growth of 17% and 26% for the three and nine month periods ended September 30, 2004,
respectively, as compared to the corresponding periods of the prior year. The increase in inventories,
which represents a 26% increase from the December 31, 2003 inventory balance, includes most of the
$7.2 million acquired at the end of June 2004 from Lanvin in connection with our new license
agreement. Factoring out the Lanvin inventory, the increase is also not unusual considering the
Company's sales growth in 2004.




    Cash flows used in investing activities normally consists of approximately $1.0 to $2.0 million
per year spent on tools and molds, depending on our new product development calendar, with the
balance of capital expenditures representing office fixtures, computer equipment and industrial
equipment needed at our distribution centers. For the nine-month period ended September 30, 2004,
cash flows used in investing activities aggregated $26.8 million. Included in this amount is approximately
$20.3 million paid for the purchase of the Lanvin license (including legal expenses and fees) and
approximately $4.4 million paid for the Nickel acquisition, net of cash acquired.




    In March 2004, our board of directors increased our cash dividend to $.12 per share, approximately
$2.3 million per annum, payable $.03 per share on a quarterly basis. This increased cash dividend in
2004 represents a small part of our cash position and is not expected to have any significant impact on
our financial position.



    We believe that funds generated from operations, supplemented by our present cash position and
available credit facilities, will provide us with sufficient resources to meet all present and reasonably
foreseeable future operating needs.




    Contractual Obligations




    We lease our office and warehouse facilities under operating leases expiring through 2013.
Obligations pursuant to these leases for the years ended December 31, 2004, 2005, 2006, 2007, 2008
and thereafter are $3.6 million, $2.9 million, $1.8 million, $1.7 million, $1.6 million and $4.2 million,
respectively.




    We are obligated under a number of license agreements for the use of trademarks and rights in
connection with the manufacture and sale of our products. Obligations pursuant to these license
agreements has increased significantly as a result of the recent signing of a new license with Burberry
and the acquisition of the Lanvin license. Obligations pursuant to all license agreements for the years
ended December 31, 2004, 2005, 2006, 2007, 2008 and thereafter are $5.2 million, $23.1 million,
$25.0 million, $27.7 million, $28.6 million and $252.1 million, respectively.





Item 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK





    General




    We address certain financial exposures through a controlled program of risk management that
primarily consists of the use of derivative financial instruments. Our French subsidiary primarily enters
into foreign currency forward exchange contracts in order to reduce the effects of fluctuating foreign
currency exchange rates. We do not engage in the trading of foreign currency forward exchange
contracts or interest rate swaps.





    Foreign Exchange Risk Management




    We periodically enter into foreign currency forward exchange contracts to hedge exposure
related to receivables denominated in a foreign currency and to manage risks related to future sales
expected to be denominated in a foreign currency. We enter into these exchange contracts for periods
consistent with our identified exposures. The purpose of the hedging activities is to minimize the effect of
foreign exchange rate movements on the receivables and cash flows of Inter Parfums, S.A., our French
subsidiary, whose functional currency is the Euro. All foreign currency contracts are denominated in
currencies of major industrial countries and are with large financial institutions, which are rated as strong
investment grade.




    All derivative instruments are required to be reflected as either assets or liabilities in the balance
sheet measured at fair value. Generally, increases or decreases in fair value of derivative instruments will
be recognized as gains or losses in earnings in the period of change. If the derivative is designated and
qualifies as a cash flow hedge, the changes in fair value of the derivative instrument will be recorded in
other comprehensive income.





    Before entering into a derivative transaction for hedging purposes, we determine that the change
in the value of the derivative will effectively offset the change in the fair value of the hedged item from a
movement in foreign currency rates. Then, we measure the effectiveness of each hedge throughout the
hedged period. Any hedge ineffectiveness is recognized in the income statement.




    We believe that our risk of loss as the result of nonperformance by any of such financial
institutions is remote and in any event would not be material. The contracts have varying maturities with
none exceeding one year. Costs associated with entering into such contracts have not been material to
our financial results. At September 30, 2004, we had foreign currency contracts in the form of forward
exchange contracts in the amount of approximately U.S. $22.3 million and GB Pounds 9.1 million.





Item 4. CONTROLS AND PROCEDURES




    Evaluation of Disclosure Controls and Procedures




    Our Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the
effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of
1934 Rule 13a-14(c)) as of the end of the period covered by this quarterly report on Form 10-Q (the
"Evaluation Date"). Based on their review and evaluation, our Chief Executive Officer and Chief
Financial Officer have concluded that, as of the Evaluation Date, our disclosure controls and
procedures were adequate and effective to ensure that material information relating to our Company
and its consolidated subsidiaries would be made known to them by others within those entities, so that
such material information is recorded, processed and reported in a timely manner, particularly during
the period in which this quarterly report on Form 10-Q was being prepared. Accordingly, no changes
were required at this time.




    Changes in Internal Controls




    There were no significant changes in our Company's internal controls or in other factors that
could significantly affect our internal controls after the Evaluation Date, or any significant deficiencies or
material weaknesses in such internal controls requiring corrective actions. As a result, no corrective
actions were taken.


















Part II. Other Information




    Items 1, 3 and 4 are omitted as they are either not applicable or have been
included in Part I.




    Item 2. Changes in Securities and Use of Proceeds




    The information contained in note 11 at page 8 relating to the exercise of outstanding stock
options by the Chief Executive Officer and the President is incorporated by reference herein. The
transactions were exempt from the registration requirements of Section 5 of the Securities Act under
Sections 4(2) and 4(6) of the Securities Act.




    In addition, a former executive officer exercised a stock option to purchase 18,000 shares of or
common stock in a transaction exempt from the registration requirements of Section 5 of the Securities
Act under Sections 4(2) of the Securities Act. All of such persons agreed to purchase our common
stock for investment and not for resale to the public.




    Item 5. Other Information




    In accordance with Section 10A(i)(2) of the Securities Exchange Act of 1934, as added by
Section 202 of the Sarbanes-Oxley Act of 2002, our company is responsible for disclosing the "non-audit services" to be performed by our auditors that were approved by our company's audit committee
during the quarterly period covered by this report. Non-audit services are defined in the law as
services other than those provided in connection with an audit or a review of the financial statements of
the company.




    During the quarterly period covered by this report, the audit committee authorized the following
non-audit services to be performed by our auditors.







    1. We authorized the engagement of Mazars LLP if deemed necessary to
provide tax consultation in the ordinary course of business for fiscal year ending 31
December 2004.




    2. We authorized the engagement of Mazars LLP if deemed necessary to
provide tax consultation as may be required on a project by project basis that would
not be considered in the ordinary course of business, of up to a $5,000 fee limit per
project, subject to an aggregate fee limit of $25,000 for fiscal year ending 31
December 2004. If we require further tax services from Mazars LLP, then the
approval of the audit committee must be obtained.



    3. If we require other services by Mazars LLP on an expedited basis such that
obtaining pre-approval of the audit committee is not practicable, then Francois
Heilbronn, the Chairman of the Committee, has authority to grant the required pre-approvals for all such services.















    Item 6. Exhibits and Reports on Form 8-K.




(a) Exhibits:




    The following documents are filed herewith:





(In millions)

2004

 

2003

 

2004

 

2003

 
                 
Selling, general & administrative

$ 25.3

 

$ 19.1

 

$ 60.6

 

$ 46.7

 
                 
Selling, general & administrative

as a % of net sales




38%


 



33%


 



35%


 



34%


 









































(b) We filed or furnished the following Current Reports on Form 8-K:





(1) Date of event - 13 September 2004, reporting Items 4.01 and 9.01;



(2) Date of event - 12 October 2004, reporting Items 1.01 and 1.02;



(3) Date of event - 13 October 2004, reporting Items 2.02, 7.01 and 9.01; and



(4) Date of event - 15 October 2004, reporting Item 4.01.










SIGNATURES




Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 12th
day of November 2004.









INTER PARFUMS, INC.





By: /s/ Russell Greenberg

Executive Vice President and

Chief Financial Officer







Exhibit 31



CERTIFICATIONS




I, Jean Madar, certify that:




1. I have reviewed this quarterly report on Form 10-Q of Inter Parfums, Inc.;




2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;




3. Based on my knowledge, the financial statements, and other financial information included in this
annual report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;




4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and have:







a) Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;




b) [omitted]




c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures as of the end of the period covered by this report based upon such evaluation; and




d) Disclosed in this report any change in the registrant's internal control over financial reporting
that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in
case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant's internal control over financial reporting; and







5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent functions):







a) all significant deficiencies and material weaknesses in the design or operation of internal
controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and




b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal control over financial reporting.







Date: November 12, 2004




/s/ Jean Madar

Jean Madar, Chief Executive Officer





 



CERTIFICATIONS




I, Russell Greenberg, certify that:




1. I have reviewed this quarterly report on Form 10-Q of Inter Parfums, Inc.;




2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;




3. Based on my knowledge, the financial statements, and other financial information included in this
annual report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;




4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and have:







a) Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;




b) [omitted]




c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures as of the end of the period covered by this report based upon such evaluation; and




d) Disclosed in this report any change in the registrant's internal control over financial reporting
that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in
case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant's internal control over financial reporting; and







5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent functions):







a) all significant deficiencies and material weaknesses in the design or operation of internal
controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and




b) any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal control over financial reporting.







Date: November 12, 2004




/s/ Russell Greenberg

Russell Greenberg

Chief Financial Officer and Principal Accounting Officer






Exhibit 32



CERTIFICATION



Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Inter Parfums, Inc., that the Quarterly
Report of Inter Parfums, Inc. on Form 10-Q for the period ended September 30, 2004, fully complies with the
requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in
such report fairly presents, in all material respects, the financial condition and results of operation of Inter
Parfums, Inc.



Date: November 12, 2004



By: /s/ Jean Madar

Jean Madar

Chief Executive Officer





Date: November 12, 2004





By: /s/ Russell Greenberg

Russell Greenberg

Executive Vice President,

Chief Financial Officer and Principal Accounting Officer




    A signed original of this written statement required by Section 906 has been provided to Inter
Parfums, Inc. and will be retained by Inter Parfums, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.







Exhibit No. Description
10.109 Lease For Asnieres (92600) -- 107, Quai Du Docteur Dervaux, (French Original)
10.109.1 Lease For Asnieres (92600) -- 107, Quai Du Docteur Dervaux, (English Translation)
10.110 Lease For 48 Rue Des Francs-Bourgeois, In Paris, 3rd District (French Original)
10.110.1 Lease For 48 Rue Des Francs-Bourgeois, In Paris,, 3rd District (English Translation)
10.111 Licence Agreement among Burberry Ltd., Inter Parfums, S.A. and Inter Parfums, Inc.
dated 12 October 2004 (Filed in Excised Form - Certain disclosure schedules and
other attachments are omitted, but will be furnished supplementally to the Commission
upon request.)
10.112 Confidential Treatment Agreement among Burberry Ltd., Inter Parfums, S.A., Inter
Parfums, Inc. and LV Capital USA, Inc., et al., dated 12 October 2004
 
10.113 Indemnity Agreement among Burberry Ltd., Inter Parfums, S.A. and Inter Parfums,
Inc. dated 12 October 2004
31 Certifications required by Rule 13a-14(a)
32 Certification Required by Section 906 of the Sarbanes-Oxley Act